Rimegepant Approved by FDA for the Acute Treatment of Migraine in Adults

CGRP receptor antagonist available as fast-acting orally disintegrating tablet On February 27, 2020, the FDA approved rimegepant (NURTEC™) for the acute treatment of migraine in adults. This is the first calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT). Rimegepant works by blocking CGRP receptors which offers an alternative treatment for those who experience inadequate efficacy, poor tolerability or have a contraindication to current acute therapies. Rimegepant is not an opioid and does not have addiction potential. Clinical Trials The FDA approved rimegepant based on results from the Phase 3 clinical trial (Study 303) and...

Updated Guidelines for Neuroimaging in Migraine

Researchers update evidence-based recommendations about when to obtain neuroimaging in patients with migraine.  In December 2019, Headache® published a review and set of evidence-based guidelines to examine the role of neuroimaging in migraine. We sat down with the guidelines’ lead author, Randolph W. Evans, MD, FAHS, to learn about the guidelines and their implications.  Updating evidence The paper provided a much-needed update on the role of neuroimaging in migraine. “When to obtain neuroimaging for the evaluation of migraine is a critical issue which affects every physician who treats migraine,” Dr. Evans says. Neuroimaging is ordered during 12% of outpatient headache...

Options for Treating Refractory Pediatric Migraine

Study finds that outpatient DHE infusion in combination with interdisciplinary care could help adolescents with refractory migraine  A recent paper in Headache® found that combining outpatient DHE infusion with interdisciplinary adjunctive care has promise as an effective treatment option for adolescents with refractory migraine. “Several years ago, we were trying to find a way to improve the quality of life of some of our most challenging patients,” co-author Jennifer Bickel, MD, FAHS, Headache Section Chief at Children’s Mercy in Kansas City, says. To help patients that were not responding to outpatient therapies, who were missing school, who needed a multidisciplinary...

Next Generation Migraine Therapies – Salt Lake City (Rescheduled)

UPDATE: This program has been rescheduled to September 12, 2020. Please take a moment to reregister for the program.

 

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers. Brought to you by the American Headache Society, the program covers diagnosis and treatment of migraine, and updates on the latest science. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and case study workshops, including interactive education elements, communication toolkits, and takeaway resources.

 

If you were registered for this program, your registration will be canceled. Once the program is rescheduled, likely for Fall 2020, you will be notified so that you may re-register should your schedule allow.

Next Generation Migraine Therapies – Chicago (Rescheduled)

UPDATE: UPDATE: This program has been rescheduled to September 26, 2020. Please take a moment to reregister for the program.

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers. Brought to you by the American Headache Society, the program covers diagnosis and treatment of migraine, and updates on the latest science. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and case study workshops, including interactive education elements, communication toolkits, and takeaway resources.

Next Generation Migraine Therapies – Seattle (Rescheduled)

UPDATE: This program has been rescheduled to October 31, 2020. Please take a moment to reregister for the program.

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers. Brought to you by the American Headache Society, the program covers diagnosis and treatment of migraine, and updates on the latest science. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and case study workshops, including interactive education elements, communication toolkits, and takeaway resources.

The Genetics of Migraine: Q&A

William Renthal, MD, PhD, discusses his work on the RNA sequence of migraine genes  It is widely accepted that migraine has a genetic component. But the genetics of migraine and how the disease develops is not yet well understood.   “We know genetic variation within certain genes increases your risk for developing migraine, but we don't understand how this happens,” says Will Renthal, MD, PhD. Dr. Renthal’s work is aimed at better understanding the genetic basis of migraine and how this information can be used to guide next-generation therapies. The American Headache Society recently spoke with Dr. Renthal about new technology...

Familial vs. Sporadic Migraine: Study Finds Little Difference

Research published in Headache® did not find a significant link between migraine severity and family history  Research shows that migraine is a complex disease. There are suspicions that there is a considerable genetic component involved with migraine. It is unknown, however, if this plays a role in disease severity, leading researchers to compare familial and sporadic migraine. This is the basis of new research published in Headache®. Thomas Hansen, PhD, and colleagues sought to determine the differences between familial and sporadic migraine. Hansen and colleagues theorized that someone with a family history of migraine would be more likely to have longer,...

Cognitive Behavioral Therapy for Migraine: Q&A

Elizabeth Seng, PhD, FAHS, discusses the significance of CBT and how it can be included as part of a patient’s migraine treatment   Change can be hard. It can be even harder for patients who are also managing migraine. So when doctors add cognitive behavioral therapy (CBT) to a patient’s migraine treatment plan, they need to have a firm understanding of CBT and how it can be used within this context. Elizabeth Seng, PhD, FAHS, is an associate professor currently focused on developing and evaluating various behavioral strategies to improve migraine and pain management. Her work also revolves around describing and...

Migraine Trigger Surprisal Model May Help Predict Attacks

Dawn C. Buse, PhD, FAHS, says novel research published in Headache® is empowering and exciting for the behavioral modification aspect of migraine treatment There is little known about specific environmental or behavioral interactions that could trigger a headache attack in a prone individual. But a study recently published in Headache® provides new insight into the relationship between potential migraine triggers and headache attacks.  Dawn C. Buse, PhD, FAHS, reviewed this article for the American Headache Society. She says the research found that a trigger surprisal model may be useful for determining headache risks caused by a diverse set of triggers...